ShinlaGen has embarked on an innovative journey in the field of immuno-oncology with its groundbreaking GEEV platform. This next-generation oncolytic virus therapy technology is set to revolutionize cancer treatment by allowing oncolytic viruses to be administered intravenously, evading immune system attacks and providing systemic anti-cancer effects.
The GEEV platform developed by ShinlaGen represents a significant advancement in cancer therapy. Unlike traditional oncolytic virus therapies that necessitate direct injection into tumors, GEEV enables intravenous administration, making it effective even for metastatic or deep-seated tumors. By expressing complement regulatory proteins on the virus surface, GEEV can evade the body’s immune response, ensuring the virus remains stable and maintains its anti-cancer efficacy through repeated administrations.
Preclinical studies have demonstrated the potential of GEEV in achieving stronger anti-cancer effects compared to direct tumor injection. The oncolytic virus ‘SJ-600’ series, utilizing the GEEV platform, not only destroys cancer cells but also triggers systemic immune responses, paving the way for a shift towards systemic cancer treatment. This development holds promise for the treatment of solid tumors with limited therapeutic options, such as liver, pancreatic, and colorectal cancers.
One of the key strengths of GEEV lies in its scalability. ShinlaGen is strategically leveraging the platform to develop new pipelines in-house and explore potential collaborations with external technologies and candidate substances. The synergistic enhancement of oncolytic viruses with immune checkpoint inhibitors, antibodies, or cell therapies is an area of great interest for global pharmaceutical companies. The platform offers opportunities for partnerships with industry leaders like Merck, Bristol Myers Squibb, and AstraZeneca, who are actively engaged in clinical trials combining oncolytic viruses with immune checkpoint inhibitors.
The versatility of the GEEV platform extends beyond oncology to other therapeutic areas, including rare diseases and infectious disease vaccines. By combining GEEV with proven technologies like immune checkpoint inhibitors, ShinlaGen anticipates accelerated global clinical trials and regulatory approvals, facilitating faster commercialization and development timelines compared to other next-generation cancer therapies.
In light of its potential impact on the pharmaceutical industry, GEEV opens doors for collaboration with domestic and international biotech companies and technology transfer on a global scale. The platform’s adaptability and efficacy make it a promising candidate for addressing unmet medical needs and advancing the frontier of cancer treatment.
As ShinlaGen pioneers this new path in immuno-oncology, the industry is poised for transformative advancements in cancer therapy, bringing hope to patients with challenging-to-treat malignancies. The culmination of innovative technologies and strategic partnerships heralds a new era in the fight against cancer, where systemic treatments and personalized medicine converge to redefine the standards of care.
Overall, ShinlaGen’s GEEV platform represents a significant leap forward in immuno-oncology, offering a versatile and scalable solution for addressing the complexities of cancer treatment. By combining cutting-edge science with strategic collaborations, ShinlaGen is at the forefront of revolutionizing cancer therapy and shaping the future of precision medicine.
Tags: clinical trials, biotech, cell therapies, regulatory
Read more on asiae.co.kr